Why the study?
Does angiotensin receptor blocker (ARB) use improve cerebrospinal fluid (CSF) amyloid and tau markers in patients with mild cognitive impairment?
Does angiotensin receptor blocker (ARB) use improve cerebrospinal fluid (CSF) amyloid and tau markers in patients with mild cognitive impairment?
Answers are grounded in this paper and cite their sources.
ARB use may slow tau accumulation in MCI; extends autopsy data but leaves open randomized trials for cognitive outcomes.
We have previously shown that angiotensin receptor blocker (ARB) use is associated with improved cognitive function in those with mild cognitive impairment (MCI) and with lower amyloid and tau content on autopsy studies. The impact of ARBs on cerebrospinal fluid (CSF) amyloid and tau biomarkers is unknown. We analyzed data from the longitudinal Alzheimer's Disease Neuroimaging Initiative to assess the impact of ARB use on CSF amyloid and tau markers.
No takes yet. Share an insight, caveat, or question.
Hajjar et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: